The safety profile was consistent with GLP-1 receptor agonists, primarily featuring transient, mild-to-moderate gastrointestinal adverse events (e.g., nausea, 55%), with low discontinuation rates (6-8.4%)
The EFSA notes, The inherent uncertainty of this [factorial] approach is reflected in the wide range of cobalamin intake calculated to compensate for estimated daily losses, depending on the assumptions taken (EFSA, 2015). Appendix D
If probiotics make you worse, stop and reassess
Many people with chronic fatigue assume they need stimulants or more sleep
From 2008 to 2019, the U.S
similar mechanisms may apply